Welcome to our dedicated page for Moleculin Biotec SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moleculin Biotech, Inc. (Nasdaq: MBRX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding Moleculin’s progress as a Phase 3 clinical stage pharmaceutical company focused on hard-to-treat tumors and certain viral infections.
Through Moleculin’s Form 8-K current reports, investors can review material events such as clinical and scientific milestones, corporate presentations, patent developments, financing transactions and listing-related communications. Recent 8-K filings have furnished press releases on positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors, updates on enrollment and unblinding plans for the pivotal MIRACLE Phase 2B/3 AML trial of Annamycin plus cytarabine (AnnAraC), and independent assessments of Annamycin’s cardiotoxicity profile. Other 8-Ks describe grant-funded and investigator-initiated research agreements for Annamycin in pancreatic cancer and glioblastoma multiforme, as well as patent grants for preliposomal Annamycin lyophilizates.
Moleculin’s filings also document capital markets and listing matters, including notices from Nasdaq regarding bid price and stockholders’ equity requirements, the company’s responses and appeal plans, and the implementation of a 1-for-25 reverse stock split with continued trading under the MBRX symbol. Additional filings cover warrant exercises, special stockholder meeting results and approvals related to equity issuances.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, such as clinical trial status, regulatory designations, patent protections and financing terms. Users can quickly scan 8-Ks and related reports to understand how Moleculin is advancing Annamycin, WP1066 and WP1122, how it is managing its Nasdaq listing, and how corporate actions may affect shareholders. This page also helps surface insider and governance-related information when reported through the company’s SEC submissions.
Moleculin Biotech reported that it entered into an agreement with Atlantic Health System to begin an investigator-initiated Phase 1B/2 single-arm study of Annamycin for third-line treatment of advanced pancreatic cancer. This design allows a clinical site to lead the study while evaluating Annamycin in a heavily pretreated setting.
The announcement was furnished under Item 7.01, with the related press release included as Exhibit 99.1. Because it is furnished rather than filed, it is intended for informational purposes. No financial terms or clinical timelines are included in the disclosure.
Moleculin Biotech, Inc. (MBRX) reported stockholder voting results from its Special Meeting. Holders approved the Nasdaq Proposal authorizing the issuance of up to 64,864,864 shares upon exercise of certain warrants issued on August 28, 2025. The proposal passed with 4,937,555 votes for, 1,479,087 against, and 142,257 abstentions, with 8,178,900 broker non-votes.
Stockholders did not approve changing the company name to Moleculin Inc., which required a majority of outstanding shares. The name proposal received 11,258,199 for, 843,364 against, and 2,636,236 abstentions. An adjournment proposal was approved with 5,589,386 for, 806,047 against, and 163,466 abstentions. As of August 28, 2025, there were 36,739,360 shares outstanding; 14,737,799 shares were present or represented by proxy, constituting a quorum.
Moleculin Biotech announced updates to its pivotal Phase 2B/3 trial ("MIRACLE") evaluating Annamycin combined with cytarabine ("AnnAraC") for adults with relapsed or refractory acute myeloid leukemia (R/R AML). The company reported active site status and recruitment updates for the multi-center, randomized, double-blind, placebo-controlled, adaptive-design study. The MIRACLE trial is described as a global approval trial with sites in the U.S., Europe and the Middle East. A press release providing these trial updates is attached to the report as Exhibit 99.1 and is furnished with the filing.
Moleculin Biotech, Inc. filed a Current Report on Form 8-K disclosing that on September 8, 2025 the company posted and is using an Investor Presentation dated September 2025 as its corporate presentation and furnished that presentation as Exhibit 99.1. The filing states the furnished presentation is not being "filed" under the Exchange Act and will not be incorporated by reference into future filings unless expressly identified. The report identifies the registrant, principal executive office address in Houston, Texas, trading symbol MBRX on NASDAQ, and includes the Exhibit list and Inline XBRL cover page reference.
Moleculin Biotech announced the start of EU enrollment in its pivotal Phase 2B/3 trial of Annamycin combined with cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia (R/R AML). The company reported that the first two subjects in the European Union have been enrolled and one subject has been treated, marking initiation of EU participation in a multi-center, randomized, double-blind, placebo-controlled, adaptive-design study.
The press release is attached as an exhibit to the company's report and is being furnished rather than filed. The disclosure focuses on clinical development progress—specifically geographic expansion of patient enrollment in a late-stage trial evaluating Annamycin plus Ara-C for R/R AML.
Moleculin Biotech, Inc. reported two corporate actions in this Current Report. Stockholders approved and the company filed a Certificate Amendment to increase authorized common shares from 100,000,000 to 500,000,000, which became effective upon filing with the Delaware Secretary of State on August 21, 2025. The company also furnished a press release dated August 27, 2025 announcing completion of its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin combined with Cytarabine (referred to as AnnAraC) for treatment of subjects with acute myeloid leukemia (AML). The Certificate Amendment and the press release are attached as exhibits.
FAQ
What is the current stock price of Moleculin Biotec (MBRX)?
What is the market cap of Moleculin Biotec (MBRX)?
